NCT00019656View on ClinicalTrials.gov

Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer

PHASE1CompletedINTERVENTIONAL
Timeline

Start Date

August 31, 1999

Conditions
LeukemiaLymphomaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative NeoplasmsUnspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

perifosine

Trial Locations (2)

20892

NCI - Center for Cancer Research, Bethesda

20892-1182

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00019656 - Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer | Biotech Hunter | Biotech Hunter